Arca
Skip to content
Tools
Tools

Multiple myeloma

Drug research and approvals for multiple myeloma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 578 studies of multiple myeloma are recruiting on ClinicalTrials.gov, Health Canada has authorized 166 drug trials for it since 2013, FDA has 48 approved and 107 open orphan designations naming it, and the EU has 36 authorised medicines for it.

  • Recruiting worldwide: 578
  • Trials authorized in Canada: 166
  • FDA orphan approvals: 48
  • EU medicines: 36

Recruiting now

Newest posted first, of 578 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 24

Phase 3 12 of 56

Phase 2 12 of 154

Phase 1 or earlier 12 of 189

How its trials ended

3,427 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 969 whose ending is known, 35% met their primary endpoint, 4% missed it and 61% stopped early.

  • Completed, result not reported1,18635%
  • Ongoing95928%
  • Met its primary endpoint33910%
  • Status unknown3139%
  • Stopped: other or unclear2718%
  • Stopped: enrollment or feasibility1645%
  • Stopped: sponsor or business decision852%
  • Stopped: lack of efficacy431%
  • Missed its primary endpoint361%
  • Stopped: safety16<1%
  • Stopped: funding15<1%

Trials authorized in Canada

The 10 newest of 166; search them all in Canada trials
Oct 20, 2026A phase 3, multicenter, open-label, randomized study to evaluate inobrodib in combination with pomalidomide and dexamethasone versus standard available therapy…Inobrodib (CCS1477) / Pomalidomide / Dexamethasone / Darzalex (daratumumab) /…Cellcentric LtdPending
Sep 25, 2026A randomized, open-label, phase 1b, crossover study to evaluate the pharmacokinetics and safety of a subcutaneous belantamab formulation with RHUPH20 versus…Belantamab (GSK2857914) / Recombinant human hyaluronidase PH20 (RHUPH20)GSKPending
Jul 17, 2026An open label phase 1b, multicenter study to evaluate the safety and efficacy of belantamab mafodotin plus cevostamab in participants with relapsed/refractory…Belantamab mafodotin / CevostamabCanadian Myeloma Research GroupPending
Jul 8, 2026A phase III, open-label, multicentre, randomised study comparing consolidation treatment with AZD0120, an autologous dual targeting chimeric antigen receptor…AZD0120 (GC012F)AstraZeneca PharmaceuticalsPending
Jun 1, 2026Safety and feasibility of teclistamab discontinuation in relapsed and refractory multiple myelomaTecvayliCiusss De L’est-De-L’île-De-Montréal – Hôpital Maisonneuve-RosemontPending
May 27, 2026A phase 3, randomized, open-label study of linvoseltamab versus daratumumab in participants with smoldering multiple myeloma at high risk of developing…Lynozyfic / DarzalexRegeneronPending
Apr 15, 2026A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone…Cevostamab (RO7187797) / Imnovid / Dexamethasone / Darzalex / Empliciti /…RocheOngoing
Apr 10, 2026A phase III, open-label, randomised, multicentre study of consolidation with a single administration of AZD0120, a dual-targeting autologous chimeric antigen…AZD0120 (GC012F)AstraZeneca PharmaceuticalsPending
Apr 2, 2026A phase 3 randomized study comparing JNJ-79635322 versus teclistamab in participants with relapsed or refractory multiple myeloma after 1 to 3 prior lines of…JNJ-79635322 / TecvayliJohnson & JohnsonOngoing
Mar 5, 2026A phase 3 randomized study comparing JNJ-79635322 and an anti-bcmaxcd3 bispecific antibody in participants with relapsed or refractory multiple myeloma who…JNJ-79635322 / TeclistamabJohnson & JohnsonOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 155
Aug 13, 2026ZenbexusIn combination with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adult patients with multiple myeloma who have…Celgene Corporation (a Bristol-Myers Squibb Company)Approved
Jul 10, 2026Sarclisa EscenaIn combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1…Sanofi-Aventis U.S. LLCApproved
Mar 5, 2026TecvayliTreatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab hyaluronidase-fihj in patients who…Janssen Research & Development, LLCApproved
Oct 23, 2025BlenrepIn combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have…GlaxoSmithKline Intellectual Property Development Ltd.Approved
Jul 2, 2025LynozyficTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including…Regeneron Pharmaceuticals, Inc.Approved
Sep 20, 2024SarclisaIn combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma…Sanofi-Aventis U.S. LLCApproved
Apr 5, 2024CarvyktiTreatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, including a…Janssen Research & Development, LLCApproved
Apr 4, 2024AbecmaTreatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an…Celgene Corporation, a Bristol-Myers Squibb CompanyApproved
Sep 8, 2023AphexdaIn combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent…Ayrmid Pharma Ltd.Approved
Aug 14, 2023ElrexfioTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including…Pfizer Inc.Approved
Aug 9, 2023TalveyTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including…Janssen Biotech, inc.Approved
Oct 25, 2022TecvayliTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including…Janssen Research & Development, LLCApproved
Jun 30, 2022KyprolisTreatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination…Onyx Therapeutics, Inc.Approved
Feb 28, 2022CarvyktiTreatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome…Janssen Research & Development, LLCApproved
Nov 30, 2021KyprolisTreatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination…Onyx Therapeutics, Inc.Approved

Medicines authorised in the EU

Newest first; 15 of 36
Jul 23, 2025BlenrepBelantamab mafodotinGlaxoSmithKline Trading Services LimitedEMA ↗
Apr 23, 2025LynozyficLinvoseltamabRegeneron Ireland Designated Activity Company (DAC)EMA ↗
Nov 14, 2024Pomalidomide TevaPomalidomide · genericTeva GmbHEMA ↗
Jul 26, 2024Pomalidomide AccordPomalidomide · genericAccord Healthcare S.L.U.EMA ↗
Jul 24, 2024Pomalidomide KrkaPomalidomide · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Jul 24, 2024Pomalidomide ZentivaPomalidomide · genericZentiva k.s.EMA ↗
Feb 16, 2024Pomalidomide ViatrisPomalidomide · genericViatris LimitedEMA ↗
Dec 7, 2023ElrexfioElranatamabPfizer Europe MA EEIGEMA ↗
Aug 21, 2023TalveyTalquetamabJanssen-Cilag International N.V.EMA ↗
Dec 16, 2022Plerixafor AccordPlerixafor · genericAccord Healthcare S.L.U.EMA ↗
Sep 19, 2022Thalidomide LipomedThalidomideLipomed GmbHEMA ↗
Aug 23, 2022TecvayliTeclistamabEMA ↗
Aug 17, 2022PepaxtiMelphalan flufenamideOncopeptides AB (publ)EMA ↗
May 25, 2022CarvyktiCiltacabtagene autoleucel · orphanJanssen-Cilag International NVEMA ↗
Aug 18, 2021AbecmaIdecabtagene vicleucel · orphanBristol-Myers Squibb Pharma EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.